

1        **Proteomic profiling of peripheral blood mononuclear cells reveals immune**  
2        **dysregulation and metabolic alterations in kidney transplant recipients with**  
3        **COVID-19**

4  
5        Giuseppe G. F. Leite<sup>1\*</sup>, Mônica Bragança Sousa<sup>1</sup>, Larissa de Oliveira C. P. Rodrigues<sup>1</sup>,  
6        Milena Karina Colo Brunialti<sup>1</sup>, José Medina-Pestana<sup>2,3</sup>, Joe M. Butler<sup>4</sup>, Hessel Peters-  
7        Sengers<sup>4,5</sup>, Lúcio Requião-Moura<sup>2,3</sup>, Reinaldo Salomão<sup>1\*</sup>

8        <sup>1</sup> Division of Infectious Diseases, Escola Paulista de Medicina, Universidade Federal  
9        de São Paulo, São Paulo 04023-900, Brazil;

10        <sup>2</sup> Division of Nephrology, Escola Paulista de Medicina, Universidade Federal de São  
11        Paulo, São Paulo 04038-031, Brazil;

12        <sup>3</sup> Hospital do Rim, Fundação Oswaldo Ramos, São Paulo 04038-002, Brazil;

13        <sup>4</sup> Center for Experimental and Molecular Medicine (CEMM), Amsterdam UMC, location  
14        University of Amsterdam, Amsterdam, The Netherlands;

15        <sup>5</sup> Department of Epidemiology and Data Science, Amsterdam UMC, location Vrije  
16        Universiteit, Amsterdam, the Netherlands;

17  
18        **\* Correspondence:**

19        Giuseppe G. F. Leite and Reinaldo Salomão, Division of Infectious Diseases, Escola  
20        Paulista de Medicina, Universidade Federal de São Paulo, São Paulo 04023-900,  
21        Brazil. Email: [giuseppe.gianini@unifesp.br](mailto:giuseppe.gianini@unifesp.br) and [rsalomao@unifesp.br](mailto:rsalomao@unifesp.br)

22  
23  
24  
25  
26  
27  
28  
29  
30  
31        **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

32 **Abstract**

33 The emergence of the Coronavirus disease 2019 (COVID-19) pandemic in 2020 has  
34 profoundly impacted global health systems, particularly affecting vulnerable  
35 populations like kidney transplant recipients (KTRs). We prospectively collected blood  
36 samples from 17 PCR-confirmed COVID-19 KTR patients and 10 non-COVID-19  
37 KTRs between May and September 2020. Using tandem mass tag-based quantitative  
38 proteomics, we characterized peripheral blood mononuclear cells (PBMCs) from KTRs  
39 alongside plasma protein biomarkers and lymphocyte counts, followed by  
40 bioinformatics analyses. Our study revealed significant proteomic alterations within  
41 PBMCs of SARS-CoV-2 infected KTRs, particularly in pathways associated with  
42 glycolysis, glucose metabolism, and neutrophil degranulation. Additionally, we  
43 observed an altered immune response marked by elevated cytokines and  
44 inflammatory mediators, coupled with decreased lymphocyte counts. Notably, patients  
45 with acute kidney injury (AKI) exhibited worse outcomes, including higher rates of ICU  
46 transfer and mechanical ventilation. Comparison of PBMC proteomic profiles between  
47 AKI and non-AKI patients highlighted distinct immune-related pathways, with AKI  
48 patients showing pronounced alterations in innate immune responses, particularly in  
49 neutrophil degranulation. Moreover, our analysis unveiled a negative correlation  
50 between T cell counts and neutrophil degranulation, suggesting potential implications  
51 for immune dysregulation in COVID-19. Our findings shed light on the complex  
52 proteomic landscape and immune responses in COVID-19-infected KTRs,  
53 emphasizing the critical need for studies focused on this population, especially in  
54 individuals with AKI. Furthermore, our observations provide valuable insights for  
55 further exploration of therapeutic interventions targeting immune dysregulation  
56 pathways in this vulnerable population.

57 **Keywords:** KTRs, PBMC, acute kidney injury, SARS-CoV-2, systems biology, mass  
58 spectrometry

59

60

61

62

63

64

65

66

67

## 68 INTRODUCTION

69 The Coronavirus disease 2019 (COVID-19) pandemic, which emerged in 2020, rapidly  
70 became a global health crisis, profoundly affecting healthcare systems, economies,  
71 and overall quality of life [1, 2]. Prior to the achievement of widespread vaccination  
72 coverage, COVID-19 presented with a wide range of clinical manifestations, from  
73 asymptomatic or presymptomatic states to varying degrees of severity, including mild,  
74 moderate, severe, and, in some cases, life-threatening complications[3].

75 Individuals with compromised immune systems, especially those undergoing  
76 immunosuppressive therapy, were particularly vulnerable. Among these high-risk  
77 groups, kidney transplant recipients (KTRs) demonstrated notably higher case-fatality  
78 rates, even after vaccination [4, 5], and exhibited lower seroconversion rates following  
79 vaccination [6]. This elevated risk underscores the compounded vulnerabilities  
80 associated with immunosuppressive treatments and the presence of multiple  
81 comorbidities in these patients [7-9].

82 The cumulative number of comorbidities associated with an immune system  
83 impairment has led to diverse responses to COVID-19 among KTRs compared with  
84 non-transplanted patients [7-9]. Investigating a panel of circulating cytokines and  
85 vascular mediators in sequential samples, we previously demonstrated that both non-  
86 KTRs and KTRs infected with COVID-19 exhibited a similar transition from admission  
87 to convalescent samples. However, the key mediators differentiating patients from  
88 their respective controls (i.e., healthy volunteers and non-infected KTRs) were distinct.  
89 For non-KTRs, the top differentiators were inflammatory cytokines, whereas for KTRs,  
90 endothelial response patterns and levels of Neutrophil Gelatinase-Associated  
91 Lipocalin (NGAL)[10], an early marker of acute kidney injury (AKI), were the most

92 significant. AKI, commonly observed in numerous systemic conditions [11], has been  
93 linked to poor outcomes, a trend that persisted in COVID-19 patients. A multicenter  
94 study involving 1,680 KTRs with COVID-19 revealed that the mortality rate was 36.0%  
95 in those with AKI, compared to 19.1% in patients maintaining normal renal function,  
96 highlighting renal function as a key predictor of survival in this population [12].

97 Recently, mass spectrometry (MS)-based proteomics, primarily focused on plasma,  
98 serum, and urine, has emerged as a powerful tool to shed light on a broad spectrum  
99 of dysregulated biological processes in KTRs with COVID-19 [13, 14]. However, the  
100 influence of SARS-CoV-2 infection on peripheral blood mononuclear cells (PBMCs) in  
101 KTRs remains a subject of ongoing investigation.

102 In this study, we employed a tandem mass tag (TMT)-based quantitative proteomic  
103 approach, coupled with bioinformatics analyses, to investigate altered proteins  
104 associated with dysregulated pathways and biological processes in kidney transplant  
105 recipients (KTRs) with COVID-19. We focused on patients with moderate to severe  
106 illness admitted to hospital wards who presented with or without acute kidney injury  
107 (AKI), as well as patients discharged from the hospital. Our aim was to provide insights  
108 into proteomic changes during the early stages of the disease and their association  
109 with AKI and post-clinical recovery.

## 110 **MATERIALS AND METHODS**

### 111 **Study Design and Population**

112 This prospective cohort study was conducted at Hospital São Paulo, a tertiary  
113 university hospital in São Paulo, Brazil [15]. The study was approved by the research  
114 ethics committee (Process number 4.453.137), and all volunteers provided written

115 informed consent prior to enrolment. The study comprised adult patients ( $\geq 18$  years  
116 old) diagnosed with COVID-19 based on positive reverse transcriptase polymerase  
117 chain reaction (RT-PCR) results from nasopharyngeal swabs. These patients were  
118 admitted to the hospital wards between May 10 and September 26, 2020. This period  
119 coincided with the first wave of the COVID-19 pandemic in Brazil (February 25, 2020,  
120 to November 5, 2020)[16], when the predominant variants observed were B.1.1.28  
121 (20–30%) and B.1.1.33 (10–35%)[16]. Patients included in the cohort had moderate  
122 to severe illness, as defined by guidelines from the National Institutes of Health and  
123 the World Health Organization[17, 18]. Exclusion criteria encompassed patients  
124 referred to outpatient clinics or admitted directly to the ICU. Among the initial 68  
125 COVID-19 patients in the cohort, 17 KTRs were selected for this study (for a  
126 comprehensive overview of the entire cohort, please refer to Peçanha-Pietrobon et al  
127 [15]). Additionally, a control group comprised 10 KTR volunteers without COVID-19  
128 symptoms (KTR controls), matched to the patient group for time since transplantation,  
129 immunosuppressive therapy, sex, and age. None of the participants in this study were  
130 vaccinated due to the unavailability of vaccines at the time of enrolment.

131 AKI was prospectively defined according to the Kidney Disease Improving Global  
132 Outcomes (KDIGO) criteria [19, 20]. Baseline graft function was assessed using  
133 creatinine levels recorded three months prior to COVID-19 diagnosis, and AKI was  
134 identified based on creatinine levels at hospital admission.

### 135 **Sample Collection**

136 Blood samples were collected from both patients and KTR controls into  
137 ethylenediaminetetraacetic acid (EDTA)-treated tubes (BD Biosciences, San Diego,  
138 CA, USA). Plasma and peripheral blood mononuclear cells (PBMCs) were separated

139 using a Ficoll gradient method (Ficoll-Paque PLUS, GE Healthcare Biosciences,  
140 Uppsala, Sweden). Plasma samples were stored at  $-80^{\circ}\text{C}$ , and PBMCs were  
141 preserved in liquid nitrogen for subsequent use.

## 142 **Measurements**

143 For detailed information on the proteomics experiments, data processing protocols,  
144 plasma biomarker assays, and the corresponding analysis methods, please refer to  
145 the supplementary methods in **Supplementary Material 1**.

## 146 **Statistical Analysis**

147 Statistical analyses were performed using R (version 4.3.0). Normality of data was  
148 assessed using the Shapiro–Wilk test and Quantile–Quantile (Q-Q) plots. Non-  
149 normally distributed data were analyzed using the Mann–Whitney U test or the  
150 Kruskal–Wallis test, while normally distributed data were analyzed using Welch's t-test  
151 or analysis of variance (ANOVA). For post hoc testing of non-normally distributed data,  
152 Dunn's test of multiple comparisons using rank sums was employed; for normally  
153 distributed continuous data, Tukey's post hoc test was conducted. Categorical  
154 variables were compared using the chi-square test or Fisher's exact test, as  
155 appropriate. Biomarker data were log-transformed to normalize their distribution. To  
156 visualize the overall differences among plasma biomarkers, principal component  
157 analysis (PCA) was conducted following previously established method [21, 22].  
158 Correlation analyses were performed using Spearman's rank correlation coefficient  
159 (Rho). Differences between groups were quantified using standardized mean  
160 differences (SMD) [23].

161

## 162 **Bioinformatics**

163 Differential protein abundance analysis was performed using the R/Bioconductor  
164 package limma. The model was adjusted for additional covariates: age, sex, time after  
165 transplantation (months), maintenance immunosuppressive therapy (class), and  
166 donor status (deceased or living). Differences in PBMC proteome profiling between  
167 the two groups were detected using the empirical Bayes moderated t-statistics, and  
168 Benjamini-Hochberg corrections were applied to all p-values to calculate the false  
169 discovery rates (FDR). Protein set enrichment analysis (PSEA) was performed using  
170 the fgsea package, with annotation information from the Reactome pathway database  
171 and hallmark gene sets from MSigDB. Additionally, single-sample PSEA (ssPSEA)  
172 was performed using the hacksig package and the Reactome pathway database. We  
173 focused on Reactome-defined immune-related pathways implicated in the host  
174 response to infection: innate immune system, adaptive immune system, cytokine  
175 signaling in the immune system, hemostasis, programmed cell death, and metabolism.

## 176 **RESULTS**

### 177 **Clinical and Epidemiological Features of the Study Participants**

178 Seventeen kidney transplant recipients (KTRs) with COVID-19, a subset of a hospital-  
179 admitted cohort with diverse clinical outcomes[15] were analyzed in this study (**Table**  
180 **1**). According to the KDIGO criteria for staging AKI, we observed that six patients  
181 (35%) did not present with AKI (stage 0), while five (29%) were classified as stage 1,  
182 three (17%) as stage 2, and three (17%) as stage 3. The mean age was 54.0 years,  
183 and most were male (n = 10, 59%). The time between COVID-19 symptom onset and  
184 hospital admission was  $7.5 \pm 4.6$  days. Primary symptoms included dyspnea (n = 12,  
185 71%), cough (n = 12, 71%), fever (n = 7, 41%), diarrhea (n = 7, 41%), and

186 nausea/vomiting (n = 7, 41%). Arterial hypertension was the most prevalent  
187 comorbidity (n = 13, 76%). Additionally, 53% of patients required ICU admission, 41%  
188 underwent mechanical ventilation, 29% required renal replacement therapy, and 41%  
189 died. Among the survivors, six participated in a clinical follow-up at an average of  
190  $29.3 \pm 5.0$  days after hospital discharge (designated as Convalescent Sample 30  
191 [CS30]). No significant differences were observed in demographic data, maintenance  
192 immunosuppressive therapy class, or donor status when comparing KTRs with  
193 COVID-19 and KTR controls (**Table 1**).

#### 194 **Global COVID-19 Perturbation of the PBMC Proteome, Plasma Proteins, and** 195 **Lymphocyte Counts in Kidney Transplant Recipients**

196 A TMT--based quantitative proteomic approach combined with liquid chromatography-  
197 tandem mass spectrometry (LC-MS/MS) was employed to quantify differentially  
198 abundant proteins (DAPs) among KTRs. The cohort was categorized based on the  
199 timing of blood sampling: patients sampled during their hospital stay (D0-wards) and  
200 those sampled approximately 30 days after discharge (CS30). These groups were  
201 compared with KTRs non-COVID-19 (KTR controls). Across seven TMT batches, a  
202 total of 2,330 proteins were identified. Focusing on proteins quantified in at least 50%  
203 of samples reduced this number to 1,403 proteins, with an average of 1,242 proteins  
204 per sample (**Supplementary Material 1: Supplementary Figure S1**). Among these  
205 1,403 proteins, 363 were differentially abundant between D0-wards and KTR controls  
206 (**Supplementary Material 1: Supplementary Figure S2A and Supplementary**  
207 **Material 1**), while 111 showed differential abundance between CS30 and KTR controls  
208 (**Supplementary Material 1: Supplementary Figure S2B and Supplementary**  
209 **Material 3**).



210 Reactome pathway enrichment analysis revealed that D0-wards patients exhibited  
211 alterations in 15 pathways compared with KTR controls, characterized by positive  
212 normalized enrichment scores (NES) in pathways associated with interferon response,  
213 innate immune system, and neutrophil degranulation. Conversely, pathways related to  
214 glycolysis and glucose metabolism exhibited negative NES. Similar NES patterns were  
215 observed in hallmark gene set enrichment analysis, with positive NES in pathways  
216 related to interferon response and inflammatory processes, and negative NES in  
217 metabolism-related pathways (**Figure 1A**). Notably, only metabolism-related  
218 pathways remained altered in CS30 patients (**Figure 1A**).

219 Plasma biomarker levels indicative of cytokine/inflammation and endothelial cell  
220 activation were significantly elevated in D0-wards patients (**Figure 1B**, and  
221 **Supplementary Material 1: Supplementary Figure S2**). Additionally, two proteins,  
222 NGAL and myeloperoxidase (MPO), were identified in both plasma and PBMCs  
223 (proteomics), demonstrating a positive moderate correlation (**Figure 1C**).  
224 Furthermore, the absolute number of lymphocytes, specifically T lymphocytes  
225 (CD3<sup>+</sup>CD45<sup>+</sup>), T cytotoxic (CD3<sup>+</sup>CD8<sup>+</sup>), and T helper (CD3<sup>+</sup>CD4<sup>+</sup>) were lower in D0-  
226 wards compared to KTR controls (**Figure 1D**). In contrast to admission samples, all  
227 plasma biomarkers (**Supplementary Material 1: Supplementary Table S1**) and  
228 absolute lymphocyte counts were comparable between CS30 and KTR controls  
229 (**Supplementary Material 1: Supplementary Table S2**), suggesting a potential return  
230 to a homeostatic state approximately 30 days after hospital discharge.

### 231 **Host response associated with acute kidney injury in KTR COVID-19 patients**

232 We compared KTR COVID-19 patients who presented with AKI (N=6) to those who  
233 did not (N=11) during ward admission. Patients with AKI presented with higher

234 Sequential Organ Failure Assessment (SOFA) scores (SMD: 0.90), increased C-  
235 Reactive Protein (CRP) levels (SMD: 0.60), and elevated creatinine levels (SMD: 1.40)  
236 upon ward admission. The AKI group experienced worse outcomes, including a higher  
237 rate of ICU transfers (SMD: 0.64), increased need for mechanical ventilation (SMD:  
238 0.86), and greater hospital mortality (SMD: 0.86). Interestingly, creatinine showed a  
239 strong positive correlation with CRP ( $Rho=0.50$ ,  $p<0.05$ ) and SOFA respiratory  
240 subscores ( $Rho=0.68$ ,  $p=0.002$ ) (**Supplementary Material 1: Supplementary Figure**  
241 **S4**).

242 We compared the PBMC proteomic alterations in AKI and non-AKI COVID-19 patients  
243 using ssPSEA for Reactome-defined immune-related pathways. Our analysis revealed  
244 alterations in seven innate immune-related pathways, three adaptive immune system  
245 pathways, and five cytokine signaling pathways in the immune system. Additionally,  
246 no alterations were observed in hemostasis, while four metabolic pathways and one  
247 programmed cell death pathway showed alterations (**Figure 2A**). Indeed, the innate  
248 immune-related pathways exhibited the most differences when comparing patients  
249 with AKI and non-AKI; these pathways also demonstrated a pattern of positive  
250 correlation with creatinine, SOFA, and CRP levels (**Figure 2B**).

251 Next, we explored the differences between KTR COVID-19 patients with AKI and non-  
252 AKI based on 15 host response biomarkers reflective of two key pathophysiological  
253 domains (cytokine/inflammatory response and endothelial cell activation/procoagulant  
254 responses) in plasma obtained on admission to the wards. First, we generated  
255 domain-specific PCA plots to compare the groups (**Figure 3**). There were significant  
256 differences in plasma biomarkers grouped in the cytokine/inflammatory response  
257 domain between patients with AKI and non-AKI. We also identified a substantial

258 overlap in the endothelial cell activation/procoagulant responses between the AKI and  
259 non-AKI groups (**Figure 3A**). The complete contribution of each biomarker to a  
260 principal component (PC) score is depicted in **Supplementary Material 1:**  
261 **Supplementary Table S3.**

262 When comparing the magnitude of individual biomarker differences expressed as  
263 Hedges' g, we observed moderate to large increases in cytokine/inflammatory markers  
264 among AKI patients, while endothelial cell activation/procoagulant markers showed  
265 small or negligible differences (**Figure 3B**). Subsequently, we evaluated the absolute  
266 number of total lymphocytes, which showed statistical differences when comparing the  
267 KTR control and COVID-19 AKI groups (**Figure 3C**). We also observed differences  
268 between the control and COVID-19 AKI groups for T helper cells. For T lymphocytes  
269 and T cytotoxic cells, differences were found in both comparisons between the KTR  
270 control vs. COVID-19 AKI groups, as well as between the KTR control vs. non-AKI  
271 groups. No differences were found in the comparison between the groups for the  
272 helper/cytotoxic ratio, B lymphocytes, and NK cells. Interestingly, for total lymphocytes,  
273 T lymphocytes, T cytotoxic cells, and T helper cells, the AKI group consistently showed  
274 lower absolute values than the non-AKI group, but with no statistical difference in the  
275 pairwise comparison.

276 Previous studies suggest an increase in immature cells, such as low-density  
277 neutrophils (LDNs) or granulocytic/polymorphonuclear myeloid-derived suppressor  
278 cells (PMN-MDSCs), in COVID-19 patients, which correlate with T cell suppression  
279 [24, 25]. LDNs commonly co-purify with PBMCs in various infections, enriching  
280 pathways like "neutrophil degranulation" in omics studies [26-31]. Therefore, we tested  
281 the correlation between the absolute values of T lymphocytes and the "neutrophil

282 degranulation" ssPSEA scores, which showed a moderate negative correlation  
283 between T lymphocytes ( $Rho=-0.43$ ,  $p=0.02$ ), T helper cells ( $Rho=-0.45$ ,  $p=0.03$ ), and  
284 the "neutrophil degranulation" score (**Supplementary Material 1: Supplementary**  
285 **Figure S5**). A weak negative and not statistically significant correlation was found  
286 between T cytotoxic cells and the "neutrophil degranulation" score ( $Rho=-0.35$ ,  
287  $p=0.08$ ).

## 288 **DISCUSSION**

289 In this study, we investigated KTRs infected with SARS-CoV-2 during the initial wave  
290 of the COVID-19 pandemic in São Paulo, Brazil. Based on the reported increased  
291 severity of COVID-19 in KTRs [4, 5, 7-9], we aimed to investigate the changes in  
292 proteomics within PBMCs in this specific population. Additionally, we explored the  
293 reported immune dysregulation and endothelial cell activation/procoagulant alterations  
294 in COVID-19 [10, 32, 33], particularly emphasizing the early stages of hospitalization  
295 while patients are in the ward. Furthermore, we investigated the reported reductions  
296 in absolute counts of lymphocytes, especially T lymphocytes and their subsets, during  
297 the acute phase of COVID-19 [34, 35], with a specific focus on KTRs.

298 The proteomic response during the acute phase of COVID-19 has been widely  
299 explored [28, 30, 31, 36], while the proteomic alterations within PBMCs of KTRs were  
300 negligible. Our study revealed proteomic alterations linked to inflammatory/immune  
301 response pathways, indicated by positive NES. Interestingly, the majority of these  
302 pathways reverted to a status similar to that of non-COVID-19 KTRs after 30 days.  
303 This pattern aligns with our previous findings from a separate cohort of COVID-19  
304 patients without KTRs [28] and is consistent with other omics reports [25, 30, 31].  
305 Notably, the glycolysis and glucose metabolism pathways exhibited a negative NES

306 and remained altered after 30 days. This metabolic alteration may affect immune cell  
307 function in pathogen recognition, as glycolysis plays a pivotal role in this process [37].  
308 This dysfunctional glycolysis profile shares similarities with findings from proteomic  
309 studies of PBMCs from critically ill COVID-19 patients [28], transcriptomic/metabolic  
310 profiling of CD14+ monocytes from patients with moderate COVID-19 [38], and single-  
311 cell RNA sequencing in monocytes and macrophages from severe patients with  
312 COVID-19-associated pulmonary aspergillosis [39]. The impaired glycolysis observed  
313 in this context may serve as an indicator of the dysfunctional host response, potentially  
314 contributing to heightened morbidity and mortality rates among KTRs.

315 Next, we investigated the proteomic alterations based on the presence of AKI, a  
316 prevalent condition in systemic illnesses affecting a significant portion of hospitalized  
317 COVID-19 patients [40]. Analysis of immune-related pathways revealed increased  
318 NES in the innate immune system, complement cascade, regulated necrosis,  
319 antimicrobial peptides, and neutrophil degranulation in COVID-19 AKI patients. These  
320 results are in line with studies discussing the pathophysiology of COVID-19–  
321 associated AKI, which is believed to be multifaceted [40], involving factors such as  
322 local and systemic inflammatory/immune response, and activation of coagulation  
323 cascades [41, 42]. This is further evidenced when examining host response  
324 biomarkers, where the PCA corresponding to this cytokine/inflammatory response  
325 domain clearly separates patients with AKI from those without, a distinction not  
326 observed in the endothelial domain. It is noteworthy that COVID-19 pathophysiology  
327 in KTRs remains largely unknown. While various general factors commonly  
328 encountered in critically ill patients, including mechanical ventilation, hypoxia,  
329 hypotension, and exposure to nephrotoxic agents, are recognized contributors to

330 kidney injury, [41] the role of direct viral infection with renal tropism, as proposed by  
331 some studies, remains unclear [43, 44].

332 Although no statistically significant differences were observed in lymphocyte counts  
333 between the AKI and non-AKI groups, it is likely that these disturbances were more  
334 severe in the AKI group, as illustrated by the finding that absolute counts of total  
335 lymphocytes and T helper cells were lower in the AKI group but not in the non-AKI  
336 group compared to the controls. Previous studies have demonstrated that T  
337 lymphocyte counts and their subsets typically decrease during the acute phase of  
338 COVID-19,[34, 35, 45]. T lymphocytes play a pivotal role in clearing the virus during  
339 SARS-CoV infection [46, 47]. Interestingly, the increase in LDNs/PMN-MDSCs may  
340 directly correlate with the decrease in the number of T cells [24, 25]. Despite their  
341 immunosuppressive properties, LDNs/PMN-MDSCs have also been associated with  
342 a pro-inflammatory phenotype, characterized by elevated levels of cytokine secretion  
343 and formation of neutrophil extracellular traps [27, 48, 49]. The presence of LDNs has  
344 been observed in previous studies [26, 28, 29], , and might be correlated to the severity  
345 of infectious diseases [25, 30]. In fact, the AKI group is more severe than the non-AKI,  
346 showing higher SOFA scores, CRP levels, and worse outcomes. This may be  
347 associated with high scores for LDNs, as well as inflammatory/immune responses.  
348 Our findings suggest a relationship between T-cell suppression and elevated levels of  
349 LDN-related proteins in PBMCs during COVID-19, particularly in patients with AKI.  
350 This association may carry important therapeutic implications for managing immune  
351 dysregulation in KTRs, highlighting the need for targeted interventions aimed at  
352 mitigating these immune alterations.

353 This study has some limitations. First, the sample size was relatively small, and all  
354 patients were enrolled at a single center. Additionally, the absence of a validation

355 cohort from another hospital in a different geographical region limits the  
356 generalizability of our findings. Moreover, we did not investigate the influence of viral  
357 load or the roles of virus variants on the results obtained. Our study was conducted in  
358 2020, so the relevance to current variants is less clear, since SARS-CoV2 variants  
359 exhibit increasing fitness, and declining pathogenicity and induced-inflammatory  
360 response [50]. Furthermore, functional assays to validate glycolysis metabolism  
361 changes and/or the potential contribution of LDNs in AKI were not conducted, which  
362 could have provided further insight into our results. Despite these limitations, our study  
363 also has notable strengths. We investigated PBMCs, a cell type that is not often  
364 explored in COVID-19 proteomics research. Our study of KTRs infected with SARS-  
365 CoV-2, along with a well-established cohort of controls, provides valuable insights and  
366 is relatively unexplored. Additionally, all individuals were unvaccinated, allowing for a  
367 clearer assessment of proteomic alterations in the absence of vaccination.  
368 Furthermore, the samples obtained in the wards and after discharge provided a  
369 comprehensive understanding of cellular proteomic changes throughout the initial  
370 symptoms of the disease and convalescence.

371 Future studies with larger, more diverse cohorts are needed to validate our findings  
372 and evaluate their long-term clinical implications. As a next step, we aim to explore  
373 patients with community-acquired infections, including both KTRs and non KTRs, to  
374 investigate broader mechanisms of immune dysregulation. These insights lay the  
375 groundwork for the development of targeted therapeutic interventions to address  
376 immune dysregulation in vulnerable populations, particularly kidney transplant  
377 recipients.

378 In summary, our study offers preliminary insights into the proteomic alterations within  
379 PBMCs of KTRs infected with SARS-CoV-2 during the early phase of the COVID-19



380 pandemic. We identified significant dysregulation in key biological pathways,  
381 particularly those involved in glycolysis, glucose metabolism, and neutrophil  
382 degranulation, which may reflect the heightened inflammatory state associated with  
383 COVID-19 in this vulnerable population. While our findings suggest an altered immune  
384 response—characterized by elevated cytokines, inflammatory mediators, and  
385 decreased lymphocyte counts—these results must be interpreted cautiously due to  
386 the small sample size. The observed association between T-cell suppression and  
387 increased levels of LDN-related proteins in AKI patients warrants further investigation,  
388 as it may hold therapeutic implications for mitigating immune dysregulation in COVID-  
389 19-infected KTRs.

### 390 **Data Availability Statement**

391 Raw and processed mass spectrometry proteomic data generated in this study are  
392 available at ProteomeXchange with the dataset identifier PXD051702.

### 393 **Author Contributions**

394 Giuseppe G. F. Leite (Conceptualization; Proteomic sample preparation; Data  
395 curation; Formal analysis; Investigation; Methodology; Visualization; Writing original  
396 draft; Writing – review & editing);

397 Mônica Bragança Sousa (Involved in collecting the data; Writing – review & editing);

398 Larissa de Oliveira C. P. Rodrigues (Involved in collecting the data; Writing – review &  
399 editing);

400 Milena Karina Colo Brunialti (Involved in collecting the data; Writing – review & editing);

401 José Medina-Pestana Writing (Intellectual input; Writing – review & editing);

402 Joe M. Butler Writing (Methodology; Intellectual input; Writing – review & editing);

403 Hessel Peters-Sengers (Methodology; Intellectual input; Writing – review & editing);

404 Lúcio Requião-Moura (Supervision - Intellectual input; Data curation; Writing original  
405 draft; Writing – review & editing);

406 Reinaldo Salomão (Funding acquisition; Supervision - Intellectual input; Data curation;  
407 Visualization; Writing original draft; Writing – review & editing)



408

409

## 410 **Funding**

411 This work was funded by FAPESP (Grants 2017/21052-0 and 2020/05110-2) to R.S.  
412 G.G.F.L. has a scholarship from FAPESP (2019/20532-3).

## 413 **Conflict of Interest**

414 The authors declare that the research was conducted in the absence of any  
415 commercial or financial relationships that could be construed as a potential conflict of  
416 interest.

## 417 **Acknowledgments**

418 The authors thank Nancy Bellei, Universidade Federal de São Paulo, for the SARS-  
419 CoV-2 PCR test; Paulo R. Abrão Ferreira, Jaqueline Sonoe Ota-Arakaki and Paula M.  
420 Peçanha-Pietrobon for the support with the selection and enrollment of patients. We  
421 thank Paolo Di Mascio and Graziella E. Ronsein for the mass spectrometry analyses  
422 performed at the Redox Proteomics Core of the Mass Spectrometry Resource at  
423 Chemistry Institute, University of São Paulo (FAPESP grant numbers 2012/12663-1  
424 and 2016/00696-3, CEPID Redoxoma 2013/07937-8).

## 425 **Supplementary material**

426 **Supplementary material 1.** Methods, Tables, and Figures.

427 **Supplementary material 2.** List of differentially abundant proteins in between D0-  
428 wards and KTR controls

429 **Supplementary material 3.** List of differentially abundant proteins in CS30 and KTR  
430 controls

431

432

## 433 REFERENCES

- 434 1. Naseer S, Khalid S, Parveen S, Abbass K, Song H, Achim MV. COVID-19  
435 outbreak: Impact on global economy. *Front Public Health*. 2022; **10**: 1009393.
- 436 2. Squires N, Garfield R, Mohamed-Ahmed O, et al. Essential public health  
437 functions: the key to resilient health systems. *BMJ Glob Health*. 2023; **8**.
- 438 3. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. *Features,*  
439 *Evaluation, and Treatment of Coronavirus (COVID-19)*. StatPearls Publishing,  
440 Treasure Island (FL), 2022.
- 441 4. Weiss A, Hendrickx R, Stensgaard E, Jellingsø M, Sommer MOA. Kidney  
442 Transplant and Dialysis Patients Remain at Increased Risk for Succumbing to  
443 COVID-19. *Transplantation*. 2023; **107**: 1136-8.
- 444 5. Demir E, Ucar ZA, Dheir H, et al. COVID-19 in Kidney Transplant Recipients: A  
445 Multicenter Experience from the First Two Waves of Pandemic. *BMC*  
446 *Nephrology*. 2022; **23**: 183.
- 447 6. Sanders JF, Messchendorp AL, de Vries RD, et al. Antibody and T-Cell  
448 Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273  
449 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With  
450 a Kidney Transplant. *Clin Infect Dis*. 2023; **76**: e188-e99.
- 451 7. Medina-Pestana J, Cristelli MP, Foresto RD, Tedesco-Silva H, Requião-Moura  
452 LR. The Higher COVID-19 Fatality Rate Among Kidney Transplant Recipients  
453 Calls for Further Action. *Transplantation*. 2022; **106**: 908-10.
- 454 8. Callaghan CJ, Mumford L, Curtis RMK, et al. Real-world Effectiveness of the  
455 Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S Vaccines  
456 Against SARS-CoV-2 in Solid Organ and Islet Transplant Recipients.  
457 *Transplantation*. 2022; **106**: 436-46.
- 458 9. Choudhary D, Kenwar D, Sharma A, et al. Risk factors for mortality in kidney  
459 transplant recipients with COVID-19: a single centre experience and case-  
460 control study. *BMC Nephrology*. 2022; **23**: 241.
- 461 10. Brunialti MKC, Leite GGF, Eburneo GS, et al. Patterns of Circulating Cytokines  
462 and Vascular Markers' Response in the Presence of COVID-19 in Kidney  
463 Transplant Recipients Compared with Non-Transplanted Patients. *Viruses*.  
464 2023; **15**: 2166.
- 465 11. Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker  
466 for human acute kidney injury. *Biomark Med*. 2010; **4**: 265-80.
- 467 12. Requião-Moura LR, Sandes-Freitas TV, Viana LA, et al. High mortality among  
468 kidney transplant recipients diagnosed with coronavirus disease 2019: Results  
469 from the Brazilian multicenter cohort study. *PLoS One*. 2021; **16**: e0254822.
- 470 13. Gisby J, Clarke CL, Medjeral-Thomas N, et al. Longitudinal proteomic profiling  
471 of dialysis patients with COVID-19 reveals markers of severity and predictors  
472 of death. *Elife*. 2021; **10**.

- 473 14. Lin H, Ma X, Xiao F, et al. Identification of a special cell type as a determinant  
474 of the kidney tropism of SARS-CoV-2. *The FEBS Journal*. 2021; **288**: 5163-78.
- 475 15. Peçanha-Pietrobon PM, Leite GGF, Hunter J, et al. The clinical course of  
476 hospitalized moderately ill COVID-19 patients is mirrored by routine  
477 hematologic tests and influenced by renal transplantation. *PLOS ONE*. 2021;  
478 **16**: e0258987.
- 479 16. Zeiser FA, Donida B, da Costa CA, et al. First and second COVID-19 waves in  
480 Brazil: A cross-sectional study of patients's characteristics related to  
481 hospitalization and in-hospital mortality. *The Lancet Regional Health –*  
482 *Americas*. 2022; **6**.
- 483 17. National Institutes of Health. COVID-19 Treatment Guidelines Panel.  
484 Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.  
485 <https://www.covid19treatmentguidelines.nih.gov/>. [Accessed Dezember 15,  
486 2022].
- 487 18. World Health Organization. Clinical management of COVID-19: living guideline,  
488 15 September 2022. 2022. <https://iris.who.int/handle/10665/362783>.  
489 [Accessed Dezember 15, 2022].
- 490 19. KDIGO AKI Work Group. KDIGO Clinical Practice Guideline for Acute Kidney  
491 Injury. *Kidney Int Suppl*. 2012; **2**: 1-141.
- 492 20. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality  
493 Initiative w. Acute renal failure - definition, outcome measures, animal models,  
494 fluid therapy and information technology needs: the Second International  
495 Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.  
496 *Critical care*. 2004; **8**: R204-12.
- 497 21. Michels EHA, Appelman B, Brabander Jd, et al. Age-related changes in plasma  
498 biomarkers and their association with mortality in COVID-19. *European*  
499 *Respiratory Journal*. 2023: 2300011.
- 500 22. Peters-Sengers H, Butler JM, Uhel F, et al. Source-specific host response and  
501 outcomes in critically ill patients with sepsis: a prospective cohort study.  
502 *Intensive Care Med*. 2022; **48**: 92-102.
- 503 23. Lin L, Aloe AM. Evaluation of various estimators for standardized mean  
504 difference in meta-analysis. *Stat Med*. 2021; **40**: 403-26.
- 505 24. Morrissey SM, Geller AE, Hu X, et al. A specific low-density neutrophil  
506 population correlates with hypercoagulation and disease severity in  
507 hospitalized COVID-19 patients. *JCI Insight*. 2021; **6**.
- 508 25. Carapito R, Li R, Helms J, et al. Identification of driver genes for critical forms  
509 of COVID-19 in a deeply phenotyped young patient cohort. *Sci Transl Med*.  
510 2022; **14**: eabj7521.
- 511 26. Leite GGF, Ferreira BL, Tashima AK, et al. Combined Transcriptome and  
512 Proteome Leukocyte's Profiling Reveals Up-Regulated Module of  
513 Genes/Proteins Related to Low Density Neutrophils and Impaired Transcription  
514 and Translation Processes in Clinical Sepsis. *Front Immunol*. 2021; **12**.

- 515 27. Einfeld AJ, Halfmann PJ, Wendler JP, et al. Multi-platform 'Omics Analysis of  
516 Human Ebola Virus Disease Pathogenesis. *Cell Host Microbe*. 2017; **22**: 817-  
517 29.e8.
- 518 28. Leite GGF, Brunialti MKC, Peçanha-Pietrobon PM, et al. Understanding  
519 COVID-19 progression with longitudinal peripheral blood mononuclear cell  
520 proteomics: Changes in the cellular proteome over time. *iScience*. 2023; **26**:  
521 107824.
- 522 29. Carapito R, Li R, Helms J, et al. Identification of driver genes for critical forms  
523 of COVID-19 in a deeply phenotyped young patient cohort. *Science  
524 Translational Medicine*. 2022; **14**: eabj7521.
- 525 30. Potts M, Fletcher-Etherington A, Nightingale K, et al. Proteomic analysis of  
526 circulating immune cells identifies cellular phenotypes associated with COVID-  
527 19 severity. *Cell Rep*. 2023; **42**: 112613.
- 528 31. Li J, Guo M, Tian X, et al. Virus-Host Interactome and Proteomic Survey Reveal  
529 Potential Virulence Factors Influencing SARS-CoV-2 Pathogenesis. *Med (N Y)*.  
530 2021; **2**: 99-112.e7.
- 531 32. Cron RQ, Caricchio R, Chatham WW. Calming the cytokine storm in COVID-  
532 19. *Nat Med*. 2021; **27**: 1674-5.
- 533 33. Sims JT, Krishnan V, Chang CY, et al. Characterization of the cytokine storm  
534 reflects hyperinflammatory endothelial dysfunction in COVID-19. *J Allergy Clin  
535 Immunol*. 2021; **147**: 107-11.
- 536 34. Cantenys-Molina S, Fernández-Cruz E, Francos P, Lopez Bernaldo de Quirós  
537 JC, Muñoz P, Gil-Herrera J. Lymphocyte subsets early predict mortality in a  
538 large series of hospitalized COVID-19 patients in Spain. *Clinical and  
539 Experimental Immunology*. 2020; **203**: 424-32.
- 540 35. Huang M, Wang Y, Ye J, Da H, Fang S, Chen L. Dynamic changes of T-  
541 lymphocyte subsets and the correlations with 89 patients with coronavirus  
542 disease 2019 (COVID-19). *Ann Transl Med*. 2020; **8**: 1145.
- 543 36. Gu X, Wang S, Zhang W, et al. Probing long COVID through a proteomic lens:  
544 a comprehensive two-year longitudinal cohort study of hospitalised survivors.  
545 *eBioMedicine*. 2023; **98**.
- 546 37. Kelly B, O'Neill LA. Metabolic reprogramming in macrophages and dendritic  
547 cells in innate immunity. *Cell Res*. 2015; **25**: 771-84.
- 548 38. Maher AK, Burnham KL, Jones EM, et al. Transcriptional reprogramming from  
549 innate immune functions to a pro-thrombotic signature by monocytes in COVID-  
550 19. *Nat Commun*. 2022; **13**: 7947.
- 551 39. Feys S, Vanmassenhove S, Kraisin S, et al. Lower respiratory tract single-cell  
552 RNA sequencing and neutrophil extracellular trap profiling of COVID-19-  
553 associated pulmonary aspergillosis: a single centre, retrospective,  
554 observational study. *Lancet Microbe*. 2024; **5**: e247-e60.
- 555 40. Nugent J, Aklilu A, Yamamoto Y, et al. Assessment of Acute Kidney Injury and  
556 Longitudinal Kidney Function After Hospital Discharge Among Patients With  
557 and Without COVID-19. *JAMA Netw Open*. 2021; **4**: e211095.

- 558 41. Legrand M, Bell S, Forni L, et al. Pathophysiology of COVID-19-associated  
559 acute kidney injury. *Nat Rev Nephrol.* 2021; **17**: 751-64.
- 560 42. Wu H, Larsen CP, Hernandez-Arroyo CF, et al. AKI and Collapsing  
561 Glomerulopathy Associated with COVID-19 and APOL 1 High-Risk Genotype.  
562 *J Am Soc Nephrol.* 2020; **31**: 1688-95.
- 563 43. Miller SE, Brealey JK. Visualization of putative coronavirus in kidney. *Kidney  
564 Int.* 2020; **98**: 231-2.
- 565 44. Delorey TM, Ziegler CGK, Heimberg G, et al. COVID-19 tissue atlases reveal  
566 SARS-CoV-2 pathology and cellular targets. *Nature.* 2021; **595**: 107-13.
- 567 45. Iannetta M, Buccisano F, Fraboni D, et al. Baseline T-lymphocyte subset  
568 absolute counts can predict both outcome and severity in SARS-CoV-2 infected  
569 patients: a single center study. *Scientific Reports.* 2021; **11**: 12762.
- 570 46. Zhao J, Zhao J, Van Rooijen N, Perlman S. Evasion by stealth: inefficient  
571 immune activation underlies poor T cell response and severe disease in SARS-  
572 CoV-infected mice. *PLoS Pathog.* 2009; **5**: e1000636.
- 573 47. Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With  
574 Coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis.* 2020; **71**: 762-  
575 8.
- 576 48. Silvestre-Roig C, Fridlender ZG, Glogauer M, Scapini P. Neutrophil Diversity in  
577 Health and Disease. *Trends Immunol.* 2019; **40**: 565-83.
- 578 49. Carmona-Rivera C, Kaplan MJ. Low-density granulocytes: a distinct class of  
579 neutrophils in systemic autoimmunity. *Semin Immunopathol.* 2013; **35**: 455-63.
- 580 50. Barh D, Tiwari S, Rodrigues Gomes LG, et al. SARS-CoV-2 Variants Show a  
581 Gradual Declining Pathogenicity and Pro-Inflammatory Cytokine Stimulation,  
582 an Increasing Antigenic and Anti-Inflammatory Cytokine Induction, and Rising  
583 Structural Protein Instability: A Minimal Number Genome-Based Approach.  
584 *Inflammation.* 2023; **46**: 297-312.

585

586

587

588

589

590

591

592

593

594

595

596

597 **Tables**

598

599 **Table 1. Baseline characteristics and clinical outcomes of KTR COVID-19**  
600 **patients at ward admission and KTR Controls**

	<b>D0-Wards, (N=17)<sup>1</sup></b>	<b>KTR Controls, (N=10)<sup>1</sup></b>	<b>p-value</b>
<b>Demographics</b>			
Age years	54.1 (11.1)	55.1 (6.3)	0.91
Male sex	10 (59%)	6 (60%)	0.96
Time after transplantation (months)	89.6 (90.6)	118.2 (119.4)	0.72
BMI	25.6 (4.1)		
Admission type, wards	17 (100%)		
<b>Maintenance immunosuppressive therapy (class)</b>			0.09
Aza/MPA+Pred	2 (12%)	0 (0%)	
CNI+Aza/MPA+Pred	15 (88%)	8 (80%)	
CNI+mTORi+Pred	0 (0%)	2 (20%)	
<b>Donor information</b>			>0.99
Deceased donor	12 (71%)	7 (70%)	
Living donor	5 (29%)	3 (30%)	
<b>AKI stages (KDIGO criteria)</b>			
0	6 (35%)		
1	5 (29%)		
2	3 (17%)		
3	3 (17%)		
<b>Comorbidity</b>			
Charlson Index	3.9 (1.5)		
Renal Disease Moderate or Severe	17 (100%)		
Diabetes	6 (35%)		
Hypertension	13 (76%)		
Obesity	1 (5.9%)		
<b>Disease severity on admission</b>			
SOFA score	2.9 (1.8)		
Temperature °C	36.8 (0.9)		
Heart rate	85.6 (13.4)		
Respiratory rate	23.2 (3.7)		
Saturation O2	92.9 (3.2)		
<b>Respiratory support</b>			
No	10 (59%)		
Non-rebreather masks	2 (12%)		



Supplemental oxygen	5 (29%)
<b>Symptoms on admission</b>	
Symptoms to wards (days)	7.5 (4.6)
Fever	7 (41%)
Cough	12 (71%)
Myalgia	6 (35%)
Fatigue/Anxiety	2 (12%)
Dyspnea	12 (71%)
Headache	4 (24%)
Nausea/Vomiting	7 (41%)
Anosmia	3 (18%)
Dysgeusia	3 (18%)
Diarrhea	7 (41%)
<b>Laboratory on admission</b>	
Hemoglobin, g/dL	12.3 (1.5)
Hematocrit (%)	37.6 (3.9)
Red Cell Distribution Width, (%)	13.9 (1.4)
Neutrophils, cells/ $\mu$ l	5,120.1 (2,128.5)
Lymphocytes, cells/ $\mu$ l	765.2 (456.3)
Monocytes, cells/ $\mu$ l	392.6 (263.9)
Platelets, cells/ $\mu$ l	196,705.9 (69,058.6)
Creatinine, mg/dL	2.1 (1.4)
C-Reactive Protein, mg/L	103.2 (50.7)
D-dimer, $\mu$ g/mL FEU	1.2 (0.7)
<b>Outcomes</b>	
Transferred to ICU	9 (53%)
Mechanical ventilation	7 (41%)
Renal replacement therapy	5 (29%)
Days in ICU	19.6 (13.3)
Death in ICU (30-day mortality)	7 (41%)

601 <sup>1</sup>Continuous variables are shown as mean  $\pm$  SD. Categorical variables are shown as absolute  
602 numbers (percentages). Abbreviation: Aza = azathioprine, CNI = Calcineurin inhibitors, MPS  
603 = mycophenolate acid, Pred = prednisone, mTORi = mammalian target of rapamycin  
604 inhibitors.

605

606

607

608

609

610

611

612

613

614 **Table 2. Demography, comorbidities, clinical and laboratory admission data, and**  
615 **outcomes stratified according to the presence of acute kidney injury**

<b>Characteristic</b>	<b>AKI (N=11)<sup>†</sup></b>	<b>non-AKI (N=6)<sup>†</sup></b>	<b>SMD</b>
<b>Demographics</b>			
Age years	51.7 (12.4)	58.2 (7.4)	-0.56
Male sex	7 (64%)	3 (50%)	0.13
BMI	24.8 (4.4)	26.9 (3.7)	-0.53
<b>Comorbidity</b>			
Charlson Index	3.8 (1.7)	4.0 (1.4)	-0.12
Diabetes	3 (27%)	3 (50%)	-0.48
Hypertension	7 (64%)	6 (100%)	-1.07
Obesity	0 (0%)	1 (17%)	-0.63
<b>Disease severity on admission</b>			
SOFA score	3.5 (1.8)	2.0 (1.4)	0.90
Temperature °C	36.9 (1.0)	36.6 (0.6)	0.42
Heart rate	83.8 (15.1)	88.8 (9.9)	-0.39
Respiratory rate	22.9 (4.6)	23.8 (1.3)	0.27
Saturation O <sub>2</sub>	92.8 (3.6)	93.0 (2.5)	-0.06
<i>Respiratory support</i>	4 (36.4%)	3 (50.0%)	0.28
<b>Symptoms on admission</b>			
Symptoms to wards (days)	8.1 (5.5)	6.5 (2.1)	0.38
Fever	5 (45%)	2 (33%)	0.25
Cough	7 (64%)	5 (83%)	-0.46
Myalgia	5 (45%)	1 (17%)	0.66
Fatigue/Anxiety	1 (9.1%)	1 (17%)	-0.23
Dyspnea	7 (64%)	5 (83%)	0.46
Headache	2 (18%)	2 (33%)	0.35
Vomiting/nausea	4 (36%)	3 (50%)	0.28
Anosmia	1 (9.1%)	2 (33%)	0.62
Dysgeusia	1 (9.1%)	2 (33%)	0.62
Diarrhea	4 (36%)	3 (50%)	0.28
<b>Laboratory on admission</b>			
Hemoglobin, g/dL	12.1 (1.5)	12.8 (1.4)	-0.46
Hematocrit (%)	37.1 (4.0)	38.7 (3.9)	-0.40
RDW, (%)	14.0 (1.7)	13.6 (0.8)	0.35
Neutrophils, cells/μl	4,846.5 (1,646.6)	5,621.5 (2,934.0)	-0.33
Lymphocytes, cells/μl	677.3 (448.4)	926.5 (464.8)	-0.55
Monocytes, cells/μl	393.8 (295.1)	390.3 (220.7)	0.01
Platelets, cells/μl	206,090.9 (75,525.4)	179,500.0 (57,479.6)	0.40



Creatinine, mg/dL	2.6 (1.5)	1.2 (0.3)	1.40
C-Reactive Protein, mg/L	112.4 (46.6)	86.4 (57.9)	0.60
D-dimer, µg/mL FEU	1.3 (0.7)	1.1 (0.9)	0.23
<b>Outcomes</b>			
Transferred to ICU	7 (64%)	2 (33%)	0.64
Mechanical ventilation	6 (55%)	1 (17%)	0.86
Renal replacement therapy	3 (27.3%)	2 (33.3%)	-0.13
Days in ICU	22.1 (13.3)	10.5 (12.0)	0.92
Hospital mortality	6 (55%)	1 (17%)	0.86

616 <sup>1</sup>Continuous variables are shown as mean ± SD. Categorical variables are shown as absolute  
617 numbers (percentages). SMD: standardized mean differences.

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

## 639 **Figure legends**

### 640 **Figure 1. Comprehensive assessment of COVID-19 impact on PBMC proteome,** 641 **plasma proteins, and lymphocyte counts.**

642 **Description Figure 1: A)** Protein set enrichment analysis (PSEA) demonstrating  
643 protein perturbations in D0-wards patients (n=17) versus KTR controls (n=10), and  
644 CS30 patients (n=6) versus KTR controls. Circle size represents the  $-\log_{10}(\text{BH-}$   
645  $\text{adjusted } p\text{-value})$ , while color denotes the normalized enrichment score (NES). Red  
646 indicates increased NES, and blue indicates decreased NES. **B)** Heatmap showing  
647 the magnitude of biomarker differences between D0-wards patients and KTR controls,  
648 quantified using Hedges' g. The red gradient highlights elevated biomarker levels in  
649 D0-wards patients. (For pairwise comparisons, see Figure S3). **C)** Scatter plot  
650 illustrating Spearman's rank correlation coefficients (Rho) between myeloperoxidase  
651 (MPO) and neutrophil gelatinase-associated lipocalin (NGAL) abundances in plasma  
652 and PBMCs (proteomic data). P-values are BH-adjusted, and **D)** Box plot comparing  
653 absolute lymphocyte counts between D0-wards COVID-19 patients and KTR controls.  
654 Statistical analyses were performed using Welch's t-test, with significance levels  
655 indicated by  $**p \leq 0.01$  and  $***p \leq 0.001$ .

656

### 657 **Figure 2. Alterations in immune-related pathways in COVID-19 patients stratified** 658 **according to the presence of acute kidney injury.**

659 **Description Figure 2: A)** Single-sample protein set enrichment analysis (ssPSEA)  
660 was performed on D0-wards COVID-19 patients stratified by the presence of acute  
661 kidney injury (AKI, n=11) and non-AKI (n=6), as well as KTR controls (n=10). The figure  
662 presents only immune-related pathways that showed significant differences between  
663 the groups. Statistical analyses were conducted using ANOVA with Tukey's post-hoc  
664 test, corrected by the Benjamini-Hochberg method. Significance is indicated as  
665 follows:  $*p \leq 0.05$ ,  $**p \leq 0.01$ ,  $***p \leq 0.001$ , and  $****p \leq 0.0001$ , and **B)** Heatmap  
666 showing Spearman's rank correlation coefficients (Rho) between the sequential organ  
667 failure assessment (SOFA) score, C-reactive protein (CRP) levels, creatinine levels,  
668 and ssPSEA pathway scores in D0-wards COVID-19 patients (n=17). Abbreviations:  
669 TLR cascades: Toll-like receptor cascades, NLR signaling: Nucleotide-binding  
670 domain, leucine rich repeat containing receptor signaling pathway, TCR signaling: T  
671 cell receptor signaling, Immunoregulatory between Lymphoid & non-Lymphoid cell:  
672 Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell, Rap1  
673 signaling: Ras-proximate-1 signaling and Metabolism of vit and cofactors: Metabolism  
674 of vitamins and cofactors.

675



676



677

678 **Figure 3. Host response biomarkers and lymphocyte count alterations in COVID-**  
679 **19 patients stratified according to the presence of acute kidney injury**


680 **Description Figure 3: A)** Principal component analysis of cytokine/inflammatory  
681 responses and endothelial cell activation/procoagulant responses. The X-axis label  
682 shows the percentage of explained variance on principal component 1, while the Y-  
683 axis label shows the percentage of explained variance on principal component 2. The  
684 ellipse indicates the central 25% of the groups. The arrows indicate the direction (arrow  
685 orientation) and strength (arrow length) of the correlation between each biomarker and  
686 the PCs. The complete contribution of each biomarker to a PC score is depicted in  
687 Supplementary Table S3. **B)** Heatmap representing the Hedges' g effect size between  
688 the AKI COVID-19 group compared with the non-AKI group (for pairwise comparison  
689 see Supplementary Table S4), and **C)** Box plot illustrating differences in lymphocyte  
690 absolute counts between D0-wards COVID-19 patients stratified according to the  
691 presence of acute kidney injury (AKI, n=11, and non-AKI, n=06) and KTR controls  
692 (n=10). Statistical analyses were performed using the ANOVA test with Tukey post-  
693 hoc test corrected by the Benjamini-Hochberg method. \* Tukey post-hoc test  $p \leq 0.05$   
694 and \*\*  $p \leq 0.01$ . Abbreviations: IL: interleukin, GDF: growth/differentiation factor, G-  
695 CSF: granulocyte-colony stimulating factor, IFN: interferon, CRP: C-Reactive Protein,  
696 NGAL: neutrophil gelatinase-associated lipocalin, MPO: Myeloperoxidase, ADAMTS-  
697 13: ADAM metalloproteinase with thrombospondin type 1 motif 13, sP-selectin: Soluble  
698 platelet selectin, sVCAM-1: Serum vascular cell adhesion molecule-1 and sICAM-1:  
699 Soluble Intercellular Adhesion Molecule-1.

700




**A****B**


**A** Cytokine and inflammatory responses



Endothelial cell and procoagulant responses



**B** Biomarker concentration in AKI COVID-19 compared with non-AKI group



**C**

